Eosinophilic fasciitis (EF) is a rare fibrosing disorder of the fascia characterized by erythema, edema, and induration of the bilateral extremities. Joint contractures and related functional limitation commonly occur owing to fascial involvement overlying the joints. Hematologic abnormalities, including peripheral eosinophilia and monoclonal gammopathy, may occur. Systemic corticosteroids are considered first-line therapy; however, prolonged treatment is frequently required in patients with EF, and a standardized therapeutic protocol is lacking.1,2 Given the dearth of systematic data guiding treatment, we evaluated the presentation and clinical response of EF in 63 patients at 3 tertiary care centers.
Wright NA, Mazori DR, Patel M, Merola JF, Femia AN, Vleugels RA. Epidemiology and Treatment of Eosinophilic FasciitisAn Analysis of 63 Patients From 3 Tertiary Care Centers. JAMA Dermatol. 2016;152(1):97-99. doi:10.1001/jamadermatol.2015.3648